Vanda Pharmaceuticals (VNDA) Liabilities and Shareholders Equity (2010 - 2026)

Vanda Pharmaceuticals has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $433.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 31.4% year-over-year to $433.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 16.88% YoY) and the FY2025 annual result came in at $488.9 million, down 25.49% from the prior year.
• Liabilities and Shareholders Equity declined to $433.5 million in Q1 2026 per VNDA's latest filing, from $488.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $656.2 million in Q4 2024 and troughed at $433.5 million in Q1 2026.
• A 5-year average of $613.6 million and a median of $634.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity gained 11.11% in 2022, then plunged 31.4% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $634.2 million in 2022, then grew by 2.24% to $648.4 million in 2023, then rose by 1.2% to $656.2 million in 2024, then slipped by 25.49% to $488.9 million in 2025, then declined by 11.34% to $433.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $433.5 million, $488.9 million, and $601.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.